PREFACE FROM THE PRESIDENT OF THE FOUNDATION COUNCIL

In its efforts to support translational cancer research and scientific education, our Foundation has increased its contributions in 2011.

The Foundation funded the initial feasibility study as part of the project to construct the AGORA – Cancer Center building, which will be located near the CHUV, and will enable scientists in fundamental research to work closely with clinicians. The architectural design competition will be launched at the beginning of 2012. Our partners: the EPFL (Ecole Polytechnique Fédérale de Lausanne), UNIL (University of Lausanne), CHUV (University Hospital) and the Ludwig Institute, as well as associated regional and national institutions, are interested in the creation of this model center in translational oncology. This place will enable innovative advances in our understanding of the distinctive mechanisms of cancer development and lead to the therapeutic solutions of tomorrow.

To reinforce its support and to promote the advance of translational oncology, the Foundation decided to create ISREC chairs intended to be integrated into the AGORA – Cancer Center. The first chair was attributed in 2010 to Professor Oliver Hantschel who is working on cellular signaling mechanisms and novel treatment strategies for hematological malignancies. The second one is in the course of attribution and the Foundation council has just decided to create a third one, always with the aim of supporting research in translational oncology. Each of these chairs is endowed with five hundred thousand francs per year for six years.

Scientific education and training has also benefited from our support. Grants were awarded to students of the UNIL/EPFL Summer Program for training courses in laboratories active in cancer research. Grants were also awarded to PhD students of the Swiss Institute for Experimental Cancer Research at EPFL as well as to UNIL students taking part in the PhD program «Cancer and Immunology». The work of these young people will help toward new understanding of the mechanisms of cancer cell growth and will allow the identification of new therapeutic targets, in particular in leukemia, melanoma or brain-colon-breast-cancers.

The challenges to triumphing over this illness are still numerous. Today, as much as in the past, the ISREC Foundation needs the commitment of everyone to enable it to pursue its mission.

Thank you for your confidence and your support.

Y. J. Paternot

EVENT SUPPORTED BY THE ISREC FOUNDATION IN 2011

HALLMARKS & HORIZONS OF CANCER
The ISREC Symposium organized from September 7th to 10th 2011 as part of the Life Sciences Symposium series of the School of Life Sciences at the Swiss Federal Institute of Technology Lausanne (EPFL) was centered on the theme Hallmarks and Horizons of Cancer. The Foundation was partner of this event which was attended by 500 participants including outstanding speakers and three Nobel prize-winners.

EVENTS ORGANIZED IN FAVOUR OF THE ISREC FOUNDATION IN 2011

AGO TROPHY
Twenty three volunteers prepared the first edition of this trophy in memory of their friend Agostino who died from cancer. Nearly 120 people came and participated in the various tournaments organized in Lonay on July 3rd 2011. The success of this event made it possible for the organizers to give CHF 4000 – to the ISREC Foundation.

«CORCELLES-LE-JORAT» MOTORBIKE RACE
Since 1998, the committee of Team Girard has been bringing together owners, riders and lovers of old motorbikes, organizing every year an event for old-timers and donating half of the profits to the ISREC Foundation.

«SQUARES OF SCIENCE» – SCIENTIFIC OBJECTS AS ARTISTIC INSPIRATION
In Zurich in January/February and in Lausanne in September/October, this traveling exhibition brought together the work of three women biologists, Nathalie Garin, Madlaina Boillat and Coline Le Brun, who have chosen to base their artistic work on microscopy photographs originating from scientific experiments. The profits from the sale of the pictures by these three artists will be donated to the ISREC Foundation.
### Projects Supported in 2011

**Total in support of scientific and academic training**

<table>
<thead>
<tr>
<th>Date</th>
<th>Grant Description</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>01.10.2008 – 30.09.2012</td>
<td>Grant « Richard and Rita Barmé » awarded to Larissa Grolimund, ISREC@EPFL</td>
<td>CHF 80'000.–</td>
</tr>
<tr>
<td></td>
<td>Research lab Prof. Joachim Lingner, ISREC@EPFL</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Function of telomeres and their molecular composition</td>
<td></td>
</tr>
<tr>
<td>01.09.2009 – 31.08.2013</td>
<td>Grant « Molecular biology of cancer and infection » awarded to Silvia Wirth, ISREC@EPFL</td>
<td>CHF 80'000.–</td>
</tr>
<tr>
<td></td>
<td>Research lab Prof. Freddy Radtke, ISREC@EPFL</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Identification of Hes1 target genes in murine and human T-ALL</td>
<td></td>
</tr>
<tr>
<td>01.06.2011 – 31.05.2015</td>
<td>Grant « Cancer and Immunology » awarded to Elena Menietti, ISREC@EPFL</td>
<td>CHF 40'000.–</td>
</tr>
<tr>
<td></td>
<td>Research lab Prof. Gian-Paolo Dotto, Department of Biochemistry, UNIL</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Role of mesenchymal Notch signaling in melanoma development and progression</td>
<td></td>
</tr>
<tr>
<td>01.06.2011 – 31.05.2015</td>
<td>Grant « Cancer and Immunology » awarded to Manuel Coutaz, ISREC@EPFL</td>
<td>CHF 40'000.–</td>
</tr>
<tr>
<td></td>
<td>Research lab Prof. Fabienne Tacchini-Cottier, Department of Biochemistry, UNIL</td>
<td></td>
</tr>
<tr>
<td></td>
<td>The role of Notch in TH17 cells differentiation and its relevance in cancer</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Awarded for training in cancer research labs</td>
<td></td>
</tr>
<tr>
<td></td>
<td>to 7 students of the School of Life Sciences, EPFL</td>
<td></td>
</tr>
<tr>
<td></td>
<td>to 6 students of the School of Biology, University of Lausanne</td>
<td></td>
</tr>
</tbody>
</table>

**Total in support of translational cancer research**

<table>
<thead>
<tr>
<th>Date</th>
<th>Grant Description</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>From 2010 (…)</td>
<td>Project AGORA – Cancer Center</td>
<td>CHF 300'000.–</td>
</tr>
<tr>
<td></td>
<td>Credit for a preliminary study in view of a new center dedicated to translational oncology, which will be built on the university hospital campus</td>
<td></td>
</tr>
<tr>
<td>01.03.2011 – 28.02.2017</td>
<td>ISREC Chair I « Translational Oncology » awarded to Oliver Hantschel, ISREC@EPFL</td>
<td>CHF 500'000.–</td>
</tr>
<tr>
<td></td>
<td>Signaling mechanisms and novel treatment strategies for hematological malignancies</td>
<td></td>
</tr>
<tr>
<td>2005 – 2013</td>
<td>Fund « Translational research – stem cells » awarded to the research groups of Professors Michel Aget, ISREC@EPFL and Ivan Stamenkovic, UNIL/CHUV</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Identification of novel anti-cancer strategies</td>
<td></td>
</tr>
<tr>
<td></td>
<td>&gt; Colon cancer research</td>
<td>CHF 38'826.–</td>
</tr>
<tr>
<td></td>
<td>&gt; Ewing sarcoma cancer research</td>
<td>CHF 50'000.–</td>
</tr>
<tr>
<td>01.01.2011 – 31.03.2012</td>
<td>Fund « Translational research – metastasis » awarded to the research group of Prof. Curzio Rüegg, University of Fribourg</td>
<td>CHF 100'000.–</td>
</tr>
<tr>
<td></td>
<td>Role of the tumor microenvironment in promoting metastasis of breast cancer relapsing after radiotherapy</td>
<td></td>
</tr>
<tr>
<td>01.06.2011 – 30.11.2012</td>
<td>Fund « Translational research – glioblastoma » awarded to Dr Olivier Preynat-Seauve, Research lab Prof. Karl-Heinz Krause, Department of Pathology and Immunology, University of Geneva</td>
<td>CHF 175'000.–</td>
</tr>
<tr>
<td></td>
<td>Embryonic stem cells for the modeling of brain tumors</td>
<td></td>
</tr>
<tr>
<td>01.06.2011 – 31.05.2013</td>
<td>Fund « Translational research – Cancer Immunotherapy » awarded to the research group of Prof. Pedro Romero, LICR@UNIL</td>
<td>CHF 155'138.–</td>
</tr>
<tr>
<td></td>
<td>CD1d-antitumor antibody bifunctional fusion molecules</td>
<td></td>
</tr>
<tr>
<td></td>
<td>to redirect the innate and adaptive immune responses to the tumor site</td>
<td></td>
</tr>
</tbody>
</table>

**Total of subsidies remitted in 2011**

CHF 1'591'464.–
To enable the Foundation to work towards its goals, the following resources are available: legacies, gifts, donations, the product of its fortune and all other resources. On December 31st 2011, the fortune of the foundation amounted to 45 millions of francs.

**Total gifts, donations, legacies, external grants received in 2011**

- 51 spontaneous gifts from private individuals: CHF 186037.–
- 2 gifts at the time of weddings: CHF 453.–
- 13 gifts from companies, associations, foundations: CHF 44760.–
- 1 gift for allocated grant / fund: CHF 46706.–
- 82 gifts in memory of deceased people: CHF 9373.–
- 9 legacies, successions: CHF 9780486.–

**Capital of the Foundation (Free funds)**

- CHF 33900000.–

**Reserved capital (Limited allocation funds)**

- Grants: CHF 880000.–
- Funds: CHF 1311000.–
- ISREC chairs: CHF 8512000.–

**SUPPORT THE ISREC FOUNDATION**

**MAKE A DONATION**

The financing of the ISREC Foundation projects is mostly assured by donations and legacies from people aware of, and keen to help, our cause. Your support is therefore essential to the pursuit of our mission: the support of cancer research projects and the training of young scientists in Switzerland.

You can support our mission in various ways:

- by a donation
- by the sponsoring of graduate students
- by the sponsoring of young professors affiliated to a Swiss university or Institute
- by the sponsoring of post-doctoral scientists for the development of projects of high competence at the national level
- by a legacy

Whether modest or more important, every donation counts and contributes to our mission.

**THANK YOU FOR YOUR SUPPORT**

ISREC Foundation – Route de la Corniche 4 – 1066 Epalinges / Lausanne / CCP 10-3224-9 (IBAN CH55 0900 0000 1000 3224 9)

or UBS, 1002 Lausanne (IBAN CH11 0024 3243 6020 3554 0) or BCV, 1001 Lausanne (IBAN CH03 0076 7000 U032 9261 3)

**FISCAL DEDUCTIONS**

- Taxes at the federal level
  A deduction of up to 20% of net income is possible, as long as the payment amounts to minimum CHF 100.–

- Taxes at the cantonal level
  The information available on the Zewo foundation web pages (www.zewo.ch) is applicable.

**ISREC FOUNDATION TAXATION**

The ISREC Foundation is recognized as a non-profit institution of public utility. Therefore your donations are exonerated from communal, cantonal and federal taxes.

**THANKS**

At the end of this year we address our deepest gratitude to all our generous donors without whom none of our projects could have been realized.

Their gesture represents an invaluable support.

To each of them, THANK YOU
ORGANIZATION

Founded on June 18th 1964, the ISREC Foundation is a private non-profit foundation.

The Foundation started its activity with the creation of the Swiss Institute for Experimental Cancer Research. Today its mission is to select and support translational cancer research projects and so to help the transfer of knowledge and collaboration between fundamental research and clinical research. The goal of these innovative projects is to translate discoveries into results and to have a positive impact on the future treatment of human cancer.

The Foundation is composed of:

THE FOUNDATION COUNCIL
The Foundation Council is the highest managing authority of the Foundation. Composed of members by right and members who are nominated, it allocates resources, appoints its members as well as those of the Scientific Board, of the Management and of the Financial Auditors. Moreover, it approves the annual budget and the Foundation accounts.

President
Mr. Yves J. Paternot
Administrator

Members by right
Prof. Franco Cavalli
Representative of the Scientific Board
Director, IOSI (Istituto Oncologico della Svizzera Italiana)

Prof. Patrick Francioli
Representative of the UNIL (University of Lausanne)
Dean, Faculty of Biology and Medicine, UNIL

Prof. Didier Trono
Representative of the EPFL
(Ecole Polytechnique Fédérale de Lausanne)
Dean, School of Life Sciences, EPFL

Nominated members
Prof. Heidi Diggelmann
Honorary Professor, UNIL
Former President, National Research Council of the Swiss National Science Foundation

Dr. Gérard Escher
Advisor, EPFL

Mrs. Catherine Labouchère
Jurist / Lawyer, Delegate of the Canton of Vaud parliament

Prof. Thomas Zeltner
Former Director, Federal Office for Public Health

THE SCIENTIFIC BOARD
The Scientific Board is composed of experts of international renown in various fields of cancer research. It establishes the scientific strategy and identifies research projects supporting collaboration between fundamental research and clinical research as well as those encouraging scientific and academic training in this domain.

President
Prof. Franco Cavalli
Director, IOSI (Istituto Oncologico della Svizzera Italiana)

Members
Prof. Adriano Aguzzi
Director, Institute of Neuropathology
University Hospital of Zurich

Prof. Martin Fey
Director, Clinic and Policlinic for Medical Oncology
University Hospital of Bern

MANAGEMENT
The Management selects, with the help of the Scientific Board, the research projects to be supported and addresses its opinion to the Foundation Council. It develops and proposes a strategy of fundraising and assumes the tasks which are allotted by the regulations of the Foundation.

Mr. Jean-Marc Tissot, Director

THE FINANCIAL AUDITORS
The financial auditors, whose tasks are allotted by law, are nominated by the Foundation Council. They are elected for one year. The 2011 mandate was entrusted to Ernst & Young, Swiss Fiduciary and Audit Company recognized by the Swiss Institute of Certified Accountants and Tax Consultants

www.isrec.ch
ISREC Foundation / Route de la Corniche 4 / 1066 Epalinges s/Lausanne
Tél. +41 (0)21 653 07 16 / Fax +41 (0)21 652 69 33 / info@isrec.ch / CCP 10-3224-9